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INTRODUCTION
Urolithiasis is one of the most common urologic condi­
tions, and it has recently been estimated that the prevalence 
of stones in Americans is 8.8% [1]. In 2000, the United States 
spent in excess of 2 billion dollars treating stone disease [2]. 
Percutaneous nephrolithotomy (PCNL) is widely accepted 
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as the ideal surgical choice for patients with a large stone 
burden and is becoming an increasingly common operation. 
In the United States, the number of  PCNLs performed 
has more than doubled in the last decade, and its use may 
continue to increase in future years [3].
Urosepsis is a well­known and potentially life­threate­
ning complication following PCNL for staghorn and large 
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renal calculi. While the overall incidence of  urosepsis in 
the reported literature is approximately 1%, the historical 
mortality rate of post­PCNL sepsis is as high as 66%–80% [4,5]. 
More commonly, patients experience less severe symptoms 
of  infection postoperatively, including fever (21%–74%), 
bacteriuria (10%–37%), and bacteremia (20%–35%) [6­8]. 
Due to the prevalence of  infection­related complications 
and potential consequences of severe infection after PCNL, 
both the American Urological Association (AUA) and 
European Association of  Urology (EAU) clinical practice 
statements have formulated specific recommendations 
regarding preoperative antibiotic prophylaxis in this patient 
population.
The AUA Best Practice Statement regarding antimicro­
bial prophylaxis recommends that all patients undergoing 
PCNL receive antibiotic prophylaxis for a duration of 
24 hours or less. Similarly, the 2015 guidelines set forth 
by the EAU confers a grade “A” recommendation for 
the treatment of  all stones >2 cm with PCNL [9]. The 
EAU guidelines also note that a single preoperative dose 
appears to be effective. However, recommendations for 
the empiric perioperative antibiotic treatment of specific 
populations (e.g., high­risk patients) are not provided. This 
is due in large part to a paucity of data in the urological 
literature [10,11]. Anecdotally, some urologists may prescribe 
extended antibiotics in those deemed to be high­risk for 
developing postoperative infection, such as patients with 
staghorn calculi or a history of  recurrent urinary tract 
infection (UTI). We sought to evaluate a cohort of  high­
risk patients undergoing PCNL and compare the rates of 
systemic inflammatory response syndrome (SIRS) in those 




After Institutional Review Board approval (201304085), 
data was retrospectively reviewed from a prospectively 
maintained database of all patients undergoing PCNL by 
2 surgeons at our institution from January 2012 to June 
2014. All patients at our institution must have a negative 
preoperative urine culture within 7 days of surgery. Those 
who had a previous positive urine culture within 30 days 
prior to surgery were excluded from analysis. High­risk 
criteria were selected based on previous literature which 
demonstrated an association between post­PCNL infectious 
complications and the following preoperative variables: 
(1) presence of  hydronephrosis, (2) stone size in greatest 
dimension of  ≥2 cm, and (3) history of  recurrent UTIs 
[12,13]. Patients were considered high­risk for postoperative 
infectious complications (e.g., SIRS) if they manifested one of 
these variables. The present study included patients with a 
history of UTI, which was defined as having symptomatic, 
culture­proven bacteriuria. Evaluation of hydronephrosis 
and quantification of stone burden were performed by both 
the treating urologist and by a fellowship­trained abdominal 
radiologist. The etiology of the hydronephrosis (i.e., presence 
of a ureteral stone versus ureteropelvic junction obstruction 
by a renal pelvic stone) was not distinguished. SIRS criteria 
were defined as having 2 or more of the following clinical 
parameters simultaneously during the postoperative 
hospitalization: (1) temperature ≥38oC or ≤36oC, (2) heart rate 
>100 beats/min, (3) respiratory rate >20 breaths/min, and 
(4) white blood cell count (WBC) >12,000/µL or <4,000/µL 
[12]. Complications were categorized via the Clavien­Dindo 
classification system [14].
2. Antibiotics
Formerly, the clinical practice of  one author (ACD) 
included 7­day oral antibiotic administration preoperatively 
for high­risk PCNL patients. After consultation with 
infectious disease specialists and pharmacists at our 
institution, the practice was changed to 2 days of 
preoperative treatment, as 2 days of treatment suffices to 
reach therapeutic serum drug levels. The clinical practice of 
another author (BMB) includes a single, preoperative dose of 
antibiotics within 60 minutes of the start of the operation. 
Therefore, 3 groups of patients exist in our institutional 
experience: those receiving 7, 2, and 0 days of antibiotics 
before PCNL. All patients received a preoperative dose of 
antibiotics within 1 hour of the start of the case. Choice 
of  preoperative, intravenous antibiotic was consistent 
with AUA guidelines (1st/2nd generation cephalosporin or 
fluoroquinolone as an alternative), with the exception of 
patients with a history of resistant organisms. Choice of oral 
antibiotic was ciprofloxacin 500 mg twice daily (adjusted 
as necessary for renal function), except in the setting of a 
previous resistant organism.
3. Surgical technique and postoperative care
The indications for PCNL were based on the composite 
of  multiple factors, including stone size, configuration, 
location, expected (or historical) composition, and patient 
preference. An external ureteral catheter was placed 
cystoscopically at the beginning of each procedure. Patients 
were positioned prone. Energy sources employed for 
lithotripsy included ultrasonic, pneumatic, and holmium 
419Investig Clin Urol 2016;57:417-423. www.icurology.org
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laser. Percutaneous access was established by fellowship­
trained interventional radiologists. Nephrostomy tube and 
ureteral stent were placed at the discretion of the urologist. 
Routinely, nephrostomy tubes were removed prior to patient 
discharge from the hospital, while ureteral stents remained 
in place for 1 to 2 weeks postoperatively. Vital signs were 
assessed after surgery every 15 minutes for the first hour, 
every 30 minutes for the second hour, and every 4 hours 
thereafter. WBC counts were checked at the discretion of 
the surgeon.
4. Statistical analysis
Fisher exact test was used to compare the rate of SIRS 
by preoperative antibiotic length. Chi­square tests and 
Kruskal­Wallis tests were used to compare categorical and 
numerical demographic variables respectively. All statistics 
were done in R version 3.2.0.
RESULTS
A total of  292 patients underwent PCNL during the 
study period, of which 138 met inclusion criteria. Twenty­
seven, 39, and 72 patients were treated with 7, 2, or 0 days 
of  preoperative antibiotics. There were no significant 
dif ferences in baseline characteristics, including age, 
body mass index, sex, duration of  surgery, stone size, 
hydronephrosis, and a history of  UTI (p>0.05) (Table 1). 
The specific signs and overall rates of SIRS for each of the 
three groups are shown in Table 2. Although there was no 
statistically significant difference in rates of SIRS between 
Table 1. Patient clinical and operative data
Variable
Days of preoperative antibiotics
p-value
7 Days (n=27) 2 Days (n=39) 0 Days (n=72)
Age (y), median (IQR) 57.0 (18.5) 62.0 (20.5) 60.5 (17.0) 0.778
BMI (kg/m2), median (IQR) 32.3 (16.5) 29.0 (10.9) 32.0 (8.3) 0.270
Stone size (mm), median (IQR) 21.0 (7.0) 20.0 (6.5) 21.5 (13.0) 0.882
Female sex, n (%) 17 (63.0) 22 (56.4) 33 (45.8) 0.259
Race, n (%) 0.743
   White 24 (88.9) 34 (87.2) 66 (91.7)
   Nonwhite 3 (11.1) 5 (12.8) 6 (8.3)
Hydronephrosis, n (%) 9 (33.3) 15 (38.5)  33 (45.8) 0.485
History of UTI, n (%) 13 (48.1)  16 (41.0) 35 (48.6) 0.731
Stone size≥ 2 cm, n (%) 23 (85.2) 29 (74.4) 51 (70.8) 0.361
Level of access, n (%) 0.763
   Below 12th rib 10 (37.0) 13 (33.3) 24 (33.3)
   Between 11th and 12th ribs 16 (59.3) 25 (64.1) 41 (57.0)
   Above 11th rib 1 (3.8) 1 (2.6) 7 (9.7)
No. of access sites (%) 0.075
   1 23 (85.2) 33 (84.6) 69 (95.7)
   2 4 (14.8) 6 (15.4) 3 (4.3)
Operative time (min), median (IQR) 124.0 (75.0) 145.0 (81.5) 100.0 (45.5) <0.001
EBL (mL), median (IQR) 20.0 (67.5) 0.0 (52.5) 15.0 (25.0) 0.564
IQR, interquartile range; BMI, body mass index; UTI, urinary tract infection; EBL, estimated blood loss.




7 Days (n=27) 2 Days (n=39) 0 Days (n=72)
Temperature ≥38oC or ≤36oC 1 (3.7) 0 (0) 1 (1.4) 0.433
Heart rate >100 beats/min 2 (7.4) 3 (7.7) 4 (5.6) 0.816
Respiratory rate >20 breaths/min 0 (0) 0 (0) 0 (0) -
White blood cell count >12,000/µL or <4,000/µL 5 (18.5) 2 (5.1) 2 (2.8) 0.022*
Met SIRS criteria 1 (3.7) 2 (5.1) 3 (4.2) ~1
Values are presented as number (%).





the groups, the number of  patients with WBC>12,000/
µL or <4,000/µL was significantly higher for the 7 days 
of  antibiotics group (18.5%, vs. 5.1% for 2 days, and 2.8% 
for 0 days, p=0.02). Two patients required postoperative 
intensive care unit admission. Urine or blood culture data 
was available for 5 of 6 patients with SIRS. Table 3 reports 
the clinical and operative data for each of the patients with 
SIRS.
In the 7­ and 2­day groups, 50 patients (75.7%) received 
oral ciprofloxacin as their preoperative antibiotic. The 
remainder of patients received antibiotics tailored to their 
history of prior positive cultures. Percutaneous access was 
supracostal in 85 patients (61.6%) and subcostal in 53 patients 
(38.4%). Mean operative time and blood loss were 127.2±57.4 
minutes and 38.1±79.1 mL, respectively. Table 1 details the 
operative data for the groups that received 7, 2, and 0 days 
of preoperative antibiotic. There was a significant difference 
in operative time, with those in the group that received 0 
days of antibiotics having a shorter time (p<0.001). Median 
length of stay was 1 day (range, 1–14 days). Nine patients 
required a second­look PCNL for residual stone burden. Six 
patients had a Clavien­Dindo grade II complication manifest 
by hemorrhage requiring transfusion. Four patients 
had Clavien­Dindo grade IIIa complications, including 
pneumothorax (2), hydrothorax (1), and hemothorax (1). 
Pneumothorax, hydrothorax, and hemothorax were managed 
with temporary chest tube drainage.
DISCUSSION
PCNL is generally safe and effective for the treatment 
of large renal calculi and is considered first­line treatment 
for staghorn stones [9,15­17]. While the risk of development 
of any postoperative UTI is relatively high (e.g., fever and 
bacteriuria develop in 21%–74% and 10%–37%, respectively) 
[6­8], the risk of a severe infectious complication (i.e., sepsis), 
is low (0.2%–4.7%) [15,18]. Thus, trepidation exists regarding 
extended perioperative antibiotic use for PCNL, as the 
sequelae of post­PCNL sepsis can be calamitous [4,5]. While 
recent work has established that single­dose antibiotic 
coverage is adequate for low­risk patients with sterile 
preoperative urine [6], little is known about preoperative 
antibiotic prophylaxis in high­risk patients. In the present 
study, no difference in occurrence of  SIRS was found 
between high­risk patients who received 7, 2, or 0 days of 
preoperative antibiotics (p=~1). 
Infectious complications following PCNL can occur 
despite sterile preoperative urine culture, making prevention 
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positive preoperative urine cultures does not eliminate the 
risk of postoperative SIRS [19]. Previous studies regarding 
antibiotic prophylaxis for PCNL have suggested that 
extended prophylactic antibiotic therapy prior to the day of 
surgery may, in fact, reduce the risk of SIRS and infectious 
complications in high­risk patients with sterile urine. Bag 
et al. [20] randomized patients to 7 days of  prophylaxis 
with nitrofurantoin versus standard prophylaxis prior to 
PCNL and noted a reduction in infectious complications: 
19% vs. 49%, respectively. Similarly, Mariappan et al. [12] 
prospectively evaluated 2 groups of  high­risk patients 
undergoing PCNL: those who received 7 days of ciprofloxacin 
versus those who received standard prophylaxis. The 
authors also noted a reduction in the incidence of  SIRS. 
The risk of SIRS for those receiving single­dose prophylaxis 
was approximately 3 times that of those receiving extended 
prophylaxis (relative risk, 2.9; 95% confidence interval, 1.3–6.3, 
p=0.004). Despite these findings, the topic of proper antibiotic 
prophylaxis in high­risk patients undergoing PCNL 
continues to debated, as evidenced by the Best Practice 
Statement put forth by the AUA. 
The results of the present study conflict with those of 
the prospective work by Mariappan et al. [12] and Bag et al. 
[20]. One major difference in our series was the rate of SIRS: 
3.7%, 5.1%, and 4.2% in those receiving 7, 2, and 0 days of 
preoperative antibiotics, whereas Mariappan et al. [12] found 
rates of SIRS to be 13.5% and 39.1% in the treatment and 
control arms, respectively. Much of this difference may be 
attributed to an ascertainment bias, given the retrospective 
nature of the present study. Furthermore, more complete 
stone culture data may have been illustrative and would be 
important in future, prospective studies. Variability in SIRS 
rates could be validated by differences in positive stone 
culture rates, as stone cultures are more closely related to 
the development of sepsis than urine culture alone [20,21]. 
Previously reported rates of SIRS after PCNL demon­
strate a wide range: 9.8%–56.7% [21,22]. This variability 
may be attributed to several causes. First, those studies 
employing prospective, standardized protocols may be 
more likely to detect clinical signs of SIRS, as opposed to 
retrospective designs. Second, the criteria for inclusion varies 
amongst PCNL studies, with some studies excluding high­
risk patients, those with worrisome findings at the time of 
access, and those with positive preoperative urine cultures. 
The definition of  SIRS has also been inconsistent across 
studies. Further, the antibiotic regimens both pre­ and 
postoperatively have differed in the literature. Although 
the rates presented herein appear to be lower than those 
in previous manuscripts, Dogan et al. [23] reported a similar 
rate of 1.5% in 338 patients. 
While the present study investigates the use of  pre­
operative antibiotics, others have evaluated the need for 
prophylactic antibiotic coverage after PCNL. Recent work by 
Deshmukh et al. [24] showed that adherence to the AUA’s 
Best Practice recommendations of  a single, preoperative 
dose did not result in a higher post­PCNL infection rate 
compared to those who received ~6 days of postoperative 
antibiotics. Similarly, Dogan et al. [25] found no difference in 
rates of post­PCNL fever in patients who received a single 
preoperative dose versus a postoperative course extending 
to nephrostomy tube removal. Seyrek et al. [22] prospectively 
randomized 198 patients to receive a single postoperative 
dose, an additional dose at 12 hours post­PCNL, or antibiotics 
until the time of nephrostomy tube removal. The authors 
found no difference in rates of SIRS between the groups. 
Tuzel et al. [26] reported on 73 patients randomized to 
a single preoperative dose or a regimen to be extended 
postoperatively until the time of nephrostomy tube removal. 
They found no difference in either fever or septicemia. 
Owing to the potential for severe infectious complications, 
the anecdotal and surgeon­specific use of  an extended 
course of antibiotics is understandable. Evidence continues 
to emerge, however, supporting the use of short­course or 
single intraoperative doses of antibiotics. Moreover, both the 
AUA and EAU have recommended such prophylaxis. The 
potential overuse of antibiotics, and the associated increase 
in highly­resistant organisms, is of  paramount concern. 
Antibiotic stewardship will be vital to the future effective 
prevention and treatment of UTIs. Cai et al. [27] reported 
their experience of antibiotic use, infection, and prevalence 
of  drug­resistant uropathogens by comparing 2,619 and 
3,529 patients who underwent a urologic procedure before 
and after the implementation of an antibiotic protocol that 
was consistent with the EAU’s guidelines. During the study 
period they found a similar rate of infections. There was also 
a significant decrease in use of antibiotics, decreased cost, 
and decreased rates of resistance to antibiotics (ciprofloxacin, 
piperacillin­tazobactam, and gentamicin).
The present study has limitations. First, it is a retro­
spective review of  a single­center experience. Certainly 
biases such as patient selection for PCNL could be manifest. 
Furthermore, due to the retrospective collection of data, the 
availability of postoperative antibiotic administration and 
complete blood, urine, and stone culture data in each patient 
is lacking. The clinical outcome of sepsis could not be studied 
in the present work due to the lack of uniform blood culture 
data. Ideally, in future prospective studies, blood cultures 




criterion, while urine and stone cultures would be obtained 
in all patients postoperatively. Differences in the culture 
collection practices were surgeon­specific; the difference 
between surgeons also explains the significant difference 
in operative times (the surgeon for the group that received 
zero of  preoperative antibiotics group had significantly 
lower operative times than the other surgeon, p<0.001). 
Additionally, the small number of patients who developed 
SIRS limits the ability to perform further statistical 
evaluations such as a multivariate analysis designed to 
identify predictors of SIRS after PCNL. Also, during the 
study period, the specific antibiotic was not standardized 
amongst surgeons, although selection was based on either 
AUA guidelines or previous positive culture sensitivities. 
Finally, the use of the terms SIRS and sepsis have become 
more precise in recent years and are now well­defined [28]. 
We chose to employ the definition used by Mariappan et al. 
[12] for simplicity and comparability. 
CONCLUSIONS
Extended preoperative antibiotic prophylaxis was 
not found to reduce the risk of SIRS after PCNL in our 
institutional experience of  high­risk patients. For these 
patients, a single preoperative dose of antibiotics is sufficient, 
which supports the recommendations made by both the 
AUA and EAU for preoperative antibiotic therapy before 
PCNL. Future, large, and prospective studies may address 
the predictors of SIRS after PCNL, investigating whether 
extended preoperative antibiotic regimens may be helpful.
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